# AMBRE (NCT04158362)

> Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04158362
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: UNICANCER
- Conditions: Cancer Metastatic
- Interventions: Paclitaxel injection; Capecitabine tablets; Letrozole 2.5mg; Anastrozole 1mg; Fulvestrant Prefilled Syringe; Abemaciclib
- Enrollment: 180
- Primary outcome: Progression-free survival (PFS)

## Commentary we found

- X threads: 7
- YouTube: 2
- Podcasts: 2
- X videos: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ambre-nct04158362

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04158362", "email": "<work email>"}; the inbox owner confirms by the emailed link.